90 related articles for article (PubMed ID: 9443619)
41. Paclitaxel and carboplatin in inoperable non-small cell lung cancer.
Kosmidis P; Mylonakis N; Fountzilas G; Samantas E; Athanasiadis A; Skarlos D
Semin Oncol; 1996 Dec; 23(6 Suppl 16):68-70. PubMed ID: 9007126
[TBL] [Abstract][Full Text] [Related]
42. Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials.
Muggia FM; Vafai D; Natale R; Israel V; Zaretsky S; McRae A; Rogers M; Jeffers S
Semin Oncol; 1995 Aug; 22(4 Suppl 9):63-6. PubMed ID: 7644931
[TBL] [Abstract][Full Text] [Related]
43. Phase I/II trial of paclitaxel and vinorelbine in advanced non-small cell lung cancer.
Grunberg SM; Dugan MC; Greenblatt MS; Ospina DJ; Valentine JW
Cancer Invest; 2005; 23(5):392-8. PubMed ID: 16193638
[TBL] [Abstract][Full Text] [Related]
44. A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting.
Sewak S; Chachoua A; Hamilton A; Taneja S; Lee J; Utate M; Sorich J; Muggia FM
Anticancer Drugs; 2003 Jan; 14(1):67-72. PubMed ID: 12544260
[TBL] [Abstract][Full Text] [Related]
45. Phase I study of paclitaxel (Taxol) plus vinorelbine (Navelbine) in patients with untreated stage IIIb and IV non-small cell lung cancer.
Breton JL; Westeel V; Jacoulet P; Mercier M; Chazard M; Depierre A
Lung Cancer; 2001; 31(2-3):295-301. PubMed ID: 11165410
[TBL] [Abstract][Full Text] [Related]
46. Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma.
Cocconi G; Mambrini A; Quarta M; Vasini G; Bella MA; Ferrozzi F; Beretta MD
Cancer; 2000 Jun; 88(12):2731-8. PubMed ID: 10870055
[TBL] [Abstract][Full Text] [Related]
47. Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer.
Tortoriello A; Facchini G; Caponigro F; Santangelo M; Benassai G; Persico G; Citarella A; Carola M; Marzano N; Iaffaioli RV
Breast Cancer Res Treat; 1998 Jan; 47(1):91-7. PubMed ID: 9493980
[TBL] [Abstract][Full Text] [Related]
48. Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines.
Culine S; Roch I; Pinguet F; Romieu G; Bressolle F
Int J Oncol; 1999 May; 14(5):999-1006. PubMed ID: 10200354
[TBL] [Abstract][Full Text] [Related]
49. A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors.
Peacock NW; Burris HA; Dieras V; Smith L; Rodriguez GI; Eckardt JR; Jones SF; Hardy J; Hohneker J; Bigley J; Von Hoff DD
Invest New Drugs; 1998; 16(1):37-43. PubMed ID: 9740542
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer.
Ramalingam S; Belani CP; Day R; Zamboni BA; Jacobs SA; Jett JR
Ann Oncol; 2004 Feb; 15(2):247-51. PubMed ID: 14760117
[TBL] [Abstract][Full Text] [Related]
51. Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel.
Fleming GF; Waggoner SE; Rotmensch J; Langhauser C
Am J Clin Oncol; 2001 Feb; 24(1):52-7. PubMed ID: 11232950
[TBL] [Abstract][Full Text] [Related]
52. Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer.
Cohen RB; Mueller SC; Haden K; de Souza P
Cancer Invest; 2000; 18(5):422-8. PubMed ID: 10834026
[TBL] [Abstract][Full Text] [Related]
53. A phase I study of sequential vinorelbine followed by paclitaxel.
Budman DR; Weiselberg L; O'Mara V; Buchbinder A; Lichtman SM; Donahue L; Adams LM
Ann Oncol; 1999 Jul; 10(7):861-3. PubMed ID: 10470436
[TBL] [Abstract][Full Text] [Related]
54. Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332.
Johnson E; Lake D; Herndon JE; Box JW; Lynch TJ; Green MR
Am J Clin Oncol; 2004 Feb; 27(1):19-23. PubMed ID: 14758128
[TBL] [Abstract][Full Text] [Related]
55. Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors.
Rigas JR; Kris MG; Miller VA; Pisters KM; Heelan RT; Grant SC; Fennelly DW; Chou TC; Sirotnak FM
Ann Oncol; 1999 May; 10(5):601-3. PubMed ID: 10416013
[TBL] [Abstract][Full Text] [Related]
56. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel--a phase II study.
Fazeny B; Zifko U; Meryn S; Huber H; Grisold W; Dittrich C
Cancer Chemother Pharmacol; 1996; 39(1-2):150-6. PubMed ID: 8995513
[TBL] [Abstract][Full Text] [Related]
57. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.
Rudin CM; Otterson GA; Mauer AM; Villalona-Calero MA; Tomek R; Prange B; George CM; Szeto L; Vokes EE
Ann Oncol; 2002 Apr; 13(4):539-45. PubMed ID: 12056703
[TBL] [Abstract][Full Text] [Related]
58. Phase-II study of vindesine and hexamethylmelamine in patients with relapsing small cell carcinoma of the lung.
Joss RA; Obrecht JP; Jungi WF; Alberto P; Sauter C; Cavalli F
Cancer Chemother Pharmacol; 1984; 13(2):148-9. PubMed ID: 6088102
[TBL] [Abstract][Full Text] [Related]
59. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial.
Sonpavde G; Ansari R; Walker P; Sciortino DF; Gabrys GT; Murdock A; Gonin R; Einhorn LH
Am J Clin Oncol; 2000 Feb; 23(1):68-70. PubMed ID: 10683082
[TBL] [Abstract][Full Text] [Related]
60. Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma.
Strumberg D; Erhard J; Harstrick A; Klaassen U; Müller C; Eberhardt W; Wilke H; Seeber S
Eur J Cancer; 1998 Jul; 34(8):1290-2. PubMed ID: 9849493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
